Zhou X, Teng B, Tilley S, Ledent C, Mustafa SJ. Metabolic hyperemia requires ATP-sensitive K ϩ channels and H2O2 but not adenosine in isolated mouse hearts. Am J Physiol Heart Circ Physiol 307: H1046 -H1055, 2014. First published August 8, 2014; doi:10.1152/ajpheart.00421.2014.-We have previously demonstrated that adenosine-mediated H2O2 production and opening of ATP-sensitive K ϩ (KATP) channels contributes to coronary reactive hyperemia. The present study aimed to investigate the roles of adenosine, H2O2, and KATP channels in coronary metabolic hyperemia (MH). Experiments were conducted on isolated Langendorffperfused mouse hearts using combined pharmacological approaches with adenosine receptor (AR) knockout mice. MH was induced by electrical pacing at graded frequencies. Coronary flow increased linearly from 14.4 Ϯ 1.2 to 20.6 Ϯ 1.2 ml·min Ϫ1 ·g Ϫ1 with an increase in heart rate from 400 to 650 beats/min in wild-type mice. Neither non-selective blockade of ARs by 8-(p-sulfophenyl)theophylline (8-SPT; 50 M) nor selective A2AAR blockade by SCH-58261 (1 M) or deletion affected MH, although resting flow and left ventricular developed pressure were reduced. Combined A2AAR and A2BAR blockade or deletion showed similar effects as 8-SPT. Inhibition of nitric oxide synthesis by N-nitro-L-arginine methyl ester (100 M) or combined 8-SPT administration failed to reduce MH, although resting flows were reduced (by ϳ20%). However, glibenclamide (KATP channel blocker, 5 M) decreased not only resting flow (by ϳ45%) and left ventricular developed pressure (by ϳ36%) but also markedly reduced MH by ϳ94%, resulting in cardiac contractile dysfunction. Scavenging of H 2O2 by catalase (2,500 U/min) also decreased resting flow (by ϳ16%) and MH (by ϳ24%) but to a lesser extent than glibenclamide. Our results suggest that while adenosine modulates coronary flow under both resting and ischemic conditions, it is not required for MH. However, H 2O2 and KATP channels are important local control mechanisms responsible for both coronary ischemic and metabolic vasodilation. coronary metabolic hyperemia; adenosine receptor knockouts; A 2A adenosine receptor; A 2B adenosine receptor; hydrogen peroxide; ATP-sensitive K ϩ channels MYOCARDIAL FUNCTION is dependent on a constant O 2 supply from the coronary circulation to myocytes. Myocardial O 2 consumption (mvO 2 ) increases whenever there is enhanced cardiac work. Because the myocardium has a very limited anerobic capacity with a high O 2 extraction (75%) (46) under resting conditions, the increased O 2 delivery during exercise mostly relies on increased coronary blood flow, termed as metabolic hyperemia. Numerous mechanisms are responsible for coronary metabolic hyperemia, allowing a balance between myocardial O 2 demand and supply. Disturbance of these mechanisms results in decreased cardiac output, hypotension, arrhythmia, heart failure, and death. Metabolic coronary vasodilation has been found to be regulated by both local metabolic feedback and adrenergic feedforward mechanisms (46). For decades, adenosine, a locally released metabolite from the myocardium, has been postulated as one of the important mechanisms responsible for metabolic coronary hyperemia (3, 4, 6, 16, 17, 19, 28) . However, recent evidence suggests that adenosine is not required for metabolic coronary vasodilation (4, 14, (47) (48) (49) , and its role in regulating resting coronary flow (CF) still remains controversial (14, (25) (26) (27) 49) . The discrepancy may be due to different animal models, differences in species, and/or the different agonists and antagonists applied in these studies. It is well established that adenosine exerts its effect through activation of four receptor subtypes, namely, A 1 and A 3 adenosine receptors (ARs), which exert constrictive effects, and A 2A and A 2B ARs, which have dilatory effects (31). The majority of these studies to characterize the functional role of adenosine in coronary hyperemia have relied heavily on adenosine-related pharmacological compounds, which may lead to misinterpretation of the data due to the mixed specificity of the agonists and antagonists for the four different ARs. In addition, the complexity of the combined intrinsic (e.g., myogenic, shear-mediated, metabolic, and endothelium-originated mediators) with extrinsic (neural hormonal regulatory mechanism) blood flow control mechanisms make whole animal study a nonoptimal model for the mechanistic exploration in local metabolic coronary blood flow regulation. Therefore, there is a need to reexamine the functional role of adenosine in coronary metabolic hyperemia using combined AR knockout (KO) mice with traditional pharmacological agents in isolated Langendorff-perfused hearts.
MYOCARDIAL FUNCTION is dependent on a constant O 2 supply from the coronary circulation to myocytes. Myocardial O 2 consumption (mvO 2 ) increases whenever there is enhanced cardiac work. Because the myocardium has a very limited anerobic capacity with a high O 2 extraction (75%) (46) under resting conditions, the increased O 2 delivery during exercise mostly relies on increased coronary blood flow, termed as metabolic hyperemia. Numerous mechanisms are responsible for coronary metabolic hyperemia, allowing a balance between myocardial O 2 demand and supply. Disturbance of these mechanisms results in decreased cardiac output, hypotension, arrhythmia, heart failure, and death.
Metabolic coronary vasodilation has been found to be regulated by both local metabolic feedback and adrenergic feedforward mechanisms (46) . For decades, adenosine, a locally released metabolite from the myocardium, has been postulated as one of the important mechanisms responsible for metabolic coronary hyperemia (3, 4, 6, 16, 17, 19, 28) . However, recent evidence suggests that adenosine is not required for metabolic coronary vasodilation (4, 14, (47) (48) (49) , and its role in regulating resting coronary flow (CF) still remains controversial (14, (25) (26) (27) 49) . The discrepancy may be due to different animal models, differences in species, and/or the different agonists and antagonists applied in these studies. It is well established that adenosine exerts its effect through activation of four receptor subtypes, namely, A 1 and A 3 adenosine receptors (ARs), which exert constrictive effects, and A 2A and A 2B ARs, which have dilatory effects (31) . The majority of these studies to characterize the functional role of adenosine in coronary hyperemia have relied heavily on adenosine-related pharmacological compounds, which may lead to misinterpretation of the data due to the mixed specificity of the agonists and antagonists for the four different ARs. In addition, the complexity of the combined intrinsic (e.g., myogenic, shear-mediated, metabolic, and endothelium-originated mediators) with extrinsic (neural hormonal regulatory mechanism) blood flow control mechanisms make whole animal study a nonoptimal model for the mechanistic exploration in local metabolic coronary blood flow regulation. Therefore, there is a need to reexamine the functional role of adenosine in coronary metabolic hyperemia using combined AR knockout (KO) mice with traditional pharmacological agents in isolated Langendorff-perfused hearts.
Increasing evidence suggests that H 2 O 2 , an endogenous metabolite, acts as an important mediator responsible for metabolic coronary vasodilation (37, 42, 53, 54) . We (42, 57) have previously demonstrated that A 2A AR-mediated H 2 O 2 production opens ATP-sensitive K ϩ (K ATP ) channels in coronary smooth muscle cells, contributing to the coronary ischemic vasodilation (42, 57) . While the K ATP channel is known to be important for coronary reactive hyperemia (1, 2, 10, 11, 42) , it remains controversial regarding its role in metabolic hyperemia (13, 15, 16, 32, 34, 35, 47, 51) . Therefore, the present study further examined whether H 2 O 2 and/or K ATP channels play an important role in coronary metabolic hyperemia using isolated Langendorff-perfused mouse hearts in the presence of catalase (an enzyme that decomposes H 2 O 2 to water) or glibenclamide (a selective K ATP channel blocker).
MATERIALS AND METHODS
Animals. The Institutional Animal Care and Use Committee of West Virginia University School of Medicine approved all experimental protocols. We followed guidelines set forth by the American Physiological Society and National Institutes of Health regarding the care and use of laboratory animals. A 2AAR and A2BAR single KO mice (A 2A KO and A2B KO mice, respectively) were generously provided by Dr. C Ledent (Universite Libre de Bruxelles, Brussels, Belgium) and Stephen Tilley (University of North Carolina, Chapel Hill, NC), respectively. A2A and A2B KO mice, both backcrossed 12 generations to the wild-type (WT) C57BL/6 background (Jackson Laboratory, Bar Harbor, ME), were bred to generate A 2A/A2B double-KO (DKO) heterozygotes. Double heterozygotes were intercrossed, and 1/16 of the offspring were A2A/A2B DKO mice. A2A/A2B DKO breeding pairs were then established. Mice were caged in a 12:12-h light-dark cycle with free access to standard chow and water. The absence of A2AAR and A2BAR at both mRNA and protein levels in A 2A KO, A2B KO, and A2A/2B DKO mice has been confirmed by our previous studies using PCR, Western blot analysis, and immunohistochemistry in the aorta, mesenteric arteries, and coronary arteries (30, 41, (43) (44) (45) 57) . Our functional data also confirmed the lack of a CGS-21680 (a selective A2AAR agonist)-induced CF response in A2A KO and A2A/2B DKO mice, the lack of a BAY 60-6583 (selective A 2BAR agonist) response in A2B KO and A2A/2B DKO mice, and the lack of an adenosine response in A 2A/2B DKO mice (41, 45) .
Langendorff-perfused mouse heart preparations. Mice (14 -17 wk) of either sex (equal ratio) were anesthetized with pentobarbital sodium (50 mg/kg body wt ip), and hearts were excised into heparinized (5 U/ml) ice-cold Krebs-Henseleit buffer containing (in mM) 119 NaCl, 11 glucose, 22 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl 2, 2 pyruvate, and 0.5 EDTA. After removal of the lung and surrounding tissue, the aorta was rapidly cannulated with a 20-gauge, blunt-ended needle and continuously perfused with 37°C buffer bubbled with 95% O2 and 5% CO2 at a constant perfusion pressure of 80 mmHg. The left atrium was removed, and a fluid-filled balloon made of plastic wrap was inserted into the left ventricle (LV) across the mitral valve. The balloon was connected to a pressure transducer for the continuous measurement of LV developed pressure (LVDP). The heart was then immersed in a water-jacketed perfusate bath maintained at 37°C and allowed to beat spontaneously. LV diastolic pressure was adjusted to 2-5 mmHg. CF was continuously measured with an ultrasonic flow probe (Transonic Systems, Ithaca, NY) placed in the aortic perfusion line. A Power Lab Chart data-acquisition system (AD Instruments, Colorado Springs, CO) was used for data acquisition. After stabilization for 20 min, hearts were then paced at 400 beats/min by two platinum wires connected to the stainless steel cannula and through the apical myocardium. Function was allowed to stabilize for another 10 min before baseline functional data were collected. The heart was then paced at gradually increasing frequencies (500, 550, 600, and 650 beats/min) to induce metabolic hyperemia. Hearts with persistent arrhythmias or LVDP of Ͻ80 mmHg were excluded from the study.
Metabolic hyperemia protocol. After stabilization, hearts were subjected to a 2 min of pacing at each frequency of 500, 550, 600, and 650 beats/min, respectively. The reason why we paced the heart from 400 to 650 beats/min (1.62-fold increase) was based on the fact that heart rate (HR) has been reported to increase by ϳ1.9-, 1.8-, 1.8-, and 1.7-fold in humans, swine, dogs, and mice, respectively, upon maximum exercise (13, 17, 29) . At the end of each pacing, the heart was allowed to stabilize for 5 min at a HR of 400 beats/min before the heart was paced at a different frequency. 8-(p-Sulfophenyl)theophylline (8-SPT; nonselective adenosine receptor antagonist, 50 M, Sigma), N-nitro-L-arginine methyl ester [L-NAME; nitric oxide (NO) synthase inhibitor, 100 M, Sigma, based on our previous study (45) showing that L-NAME at Ն10
Ϫ5 reached its maximum inhibition on resting CF and 5=-(N-ethylcarboxamido)adenosine (nonselective adenosine agonist)-induced CF responses], SCH-58261 (selective A 2AAR antagonist, Ki ϭ 1.3 nM, 1 M, Tocris Bioscience), CVT-6883 (selective A2BAR antagonist, Ki ϭ 22 nM, 1 M, Tocris Bioscience), catalase (the enzyme that decomposes H2O2 to water, 2,500 U/ml, Sigma), or glibenclamide (KATP channel blocker, 5 M, Sigma) were delivered into the aortic perfusion line for 15 min using a microinjection pump (Harvard Apparatus, Holliston, MA) as 1% of CF. In the presence of each pharmacological reagent, a second pacing-induced functional hyperemia was elicited. Time-matched control experiments with two consecutive inductions of functional hyperemia showed no differences in baseline function as well as the magnitude of pacing-induced changes in CF (n ϭ 3 animals).
Data analysis and statistics. All data collected were analyzed by LabChart 7.0 software. Baseline CF, LVDP, and dP/dt were calculated as mean values after each heart was paced at 400 beats/min for 10 min. Mean CF was calculated during the 2-min pacing at each frequency. Because absolute CF rates changed proportionally with heart mass, CF was normalized by heart mass and presented as milliliters per gram of wet heart weight per minute. Because mvO 2 is a function of HR, cardiac contractility, ventricular wall tension, and muscle shortening (9, 12, 20) , it is represented by the rate-pressure product (RPP). To examine the relationship between mvO 2 and RPP, PO2 of the inflow (Pi{O2}; an indication of arterial O2 tension) and outflow perfusate (Po{O2}; an indication of venous O2 tension collected through a tube inserted in the right atrium close to the coronary sinus) were measured using a GEM Premier 4000 gas analyzer (n ϭ 2). Because of the absence of hemoglobin in the perfusion buffer, O 2 content is dependent solely on the O2 solubility in the buffer at 37°C, which was 0.023 ml O2·ml buffer Ϫ1 ·atm Ϫ1 (39) . mvO2 was calculated using the following equation: mvO2 ϭ CF ϫ (Pi{O2} Ϫ Po{O2}) ϫ 0.023/760, as previously described (39) . As expected, mvO2 linearly correlated with RPP as hearts were paced at graded frequencies (mvO2 ϭ1.49 ϫ RPP ϩ 101.5, R 2 ϭ 0.9596, P Ͻ 0.01), indicating that mvO2 is a function of the HR and LVDP product.
Least-square linear regression analysis was conducted between HR or RPP, and CF to calculate the slope of the relationship. The slope of each curve was compared before and after drug treatment or between groups. All data are presented as means Ϯ SE; n represents the number of animals unless otherwise indicated. Paired t-test was used for paired data analysis. One-way ANOVA was used to compare the data between groups. The effect of treatment on the relation between two variables was analyzed by analysis of covariance using GraphPad Prism5. P values of Ͻ0.05 were considered as statistically significant.
RESULTS

Baseline function from WT, A 2A KO, A 2B KO, and A 2A/2B
DKO mouse hearts. Baseline functional parameters of isolated mouse hearts were recorded at 10 min of pacing (400 beats/ min) after 20-min stabilization. There were no statistically significant differences in the heart-to-body weight ratio and maximum ϪdP/dt among all animal strains, although ϩdP/dt had a trend to be less in A 2A KO, A 2B KO, or A 2A/2B DKO mice compared with WT mice. Baseline CF as well as LVDP were significantly lower in KO mice compared with WT mice (P Ͻ 0.05 vs. WT mice; Table 1) .
Pacing-induced coronary hyperemia in the absence or presence of 8-SPT. The CF response in isolated hearts of WT mice was measured before and after the addition of 8-SPT (50 M, a nonselective adenosine antagonist, n ϭ 6). Under control conditions, mean CF increased significanlty from 14.4 Ϯ 1.2 to 16.8 Ϯ 1.1, 18.5 Ϯ 1.3, 19.5 Ϯ 0.9, and 20.6 Ϯ 1.2 ml·min Ϫ1 ·g Ϫ1 when hearts were paced from 400 to 500, 550, 600, and 650 beats/min, respectively (Fig. 1A) . The increased CF linearly correlated with the enhanced mvO 2 To confirm the antagonistic ability of 8-SPT against adenosine, we examined the effect of 8-SPT at the same concentration (50 M) on adenosine (10 Ϫ9 ϳ10 Ϫ5 M)-induced CF responses. 8-SPT significantly decreased both baseline CF (from 13.2 Ϯ 0.55 to 10.8 Ϯ 0.52 ml·min Ϫ1 ·g Ϫ1 , n ϭ 3, P Ͻ 0.05) as well as the adenosine-induced CF increase (maximal coronary flow was reduced from 35 Ϯ 1.4 to 15.4 Ϯ 1.5 ml·min Ϫ1 ·g
Ϫ1
, P Ͻ 0.05; Fig. 1D ). Combined effect of L-NAME and 8-SPT on pacing-induced coronary hyperemia. Baseline CF was significantly decreased by L-NAME (10 Ϫ4 M) from 18.0 Ϯ 0.86 to 14.8 Ϯ 0.78 ml·min Ϫ1 ·g Ϫ1 (P Ͻ 0.05, n ϭ 8; Fig. 2A ). However, the pacing-induced CF increase was not affected by L-NAME (CF increased linearly from 14.8 Ϯ 0.78 to 22.9 Ϯ 1.53 ml·min Ϫ1 ·g Ϫ1 when hearts were paced from 400 to 650 beats/ min; Fig. 2, A and B) . The slope of the relationship between HR or RPP and CF was not significantly changed before or after the addition of L-NAME (P Ͼ 0.05), and the linear curve was shifted downward in a parallell manner. Concomitant with the decreased baseline flow, LVDP was signficantly diminshed by L-NAME from 110 Ϯ 5.9, 130 Ϯ 4.9, 136 Ϯ 3.5, 135 Ϯ 3.5, All values are means Ϯ SE. WT, wild type; A2A KO, A2A adenosine receptor knockout; A2B KO, A2B adenosine receptor knockout; A2A/AB DKO, A2A/2B adenosine receptor double knockout. *P Ͻ 0.05 compared with WT. and 134 Ϯ 3.4 to 88 Ϯ 6.1, 104 Ϯ 6.4, 112 Ϯ 44.8, 112 Ϯ 4.8, and 116 Ϯ 4.1 mmHg when hearts were paced at 400, 500, 550, 600, and 650 beats/min, respectively (P Ͻ 0.05; Fig. 2C ).
In four of eight animals, 8-SPT (50 M) was added in the presence of L-NAME. 8-SPT did not further decrease baseline CF, nor did it affect pacing-induced hyperemia (P Ͼ 0.05 vs. L-NAME; Fig. 2, A-C) .
Effect , and HR and LVDP (C) under control conditions (n ϭ 8), in the presence of L-NAME (nitric oxide synthase inhibitor, 100 M, n ϭ 4), and in the combined presence of 8-SPT (50 M) and L-NAME (100 M, n ϭ 4). *P Ͻ 0.05, significant difference from the control curve (A and B) and versus control (C). , and HR and LVDP (C) in control wild-type (WT) mice (n ϭ 6), A2AAR knockout (A2A KO) mice (n ϭ 9), and WT mice treated with SCH-58261 (selective A2AAR antagonist, 1 M, n ϭ 6). *P Ͻ 0.05, significant difference between the curves or significant difference versus control; #P Ͻ 0.05, significant difference versus A2A KO mice.
(P Ͻ 0.05; Fig. 3C ). However, after A 2A AR blockade, CF still increased from 11.3 Ϯ 0.70 to 16.3 Ϯ 0.54 ml·min Ϫ1 ·g Ϫ1 when hearts were paced from 400 to 650 beats/min. The slope of the relationship between HR or RRP and CF was not different before or after A 2A AR blockade (P Ͼ 0.05; Fig. 3, A and B) .
We further examined the effect of A 2A AR deletion on pacing-induced coronary hyeremia using A 2A KO mice (n ϭ 9). Baseline CF and LVDP were 14.4 Ϯ 0.56 ml·min
and 90 Ϯ 3.9 mmHg, respectively, which were significantly lower than those in WT mice (Table 1 and Fig. 3 ) but were higher than those in WT mice treated with SCH-58261 (P Ͻ 0.05; Fig. 3, A and C) . Consistent with the effect of SCH-58261, A 2A AR deletion did not affect the pacing-induced CF increase, although receptor deletion resulted in a parallel downward shift of the relationship between RPP or HR and CF (Fig. 3, A and B) . Ϫ1 , respectively when hearts were paced from 400 to 650 beats/min; Fig.  4, A-C) . The slope of the relationship between HR and/or RPP and CF under each experimental condition was not significantly different from WT mice (Fig. 4, A-C) .
To confirm the role of A 2A ARs and A 2B ARs in coronary metabolic hyperemia, we further examined the hyperemic response in A 2A/2B DKO mice (n ϭ 6). Baseline CF (13.4 Ϯ 0.52 ml·min Ϫ1 ·g Ϫ1 ) and LVDP (88 Ϯ 2.5 mmHg) were lower than those in WT mice (P Ͻ 0.05) and were less than those in either A 2A KO or A 2B KO mice, although they did not reach statistical significance (Table 1 and Fig. 4, E and F) . However, the pacing-induced hyperemic response was not affected (CF increased from 13.3 Ϯ 0.52 to 19.9 Ϯ 0.73 ml·min Ϫ1 ·g Ϫ1 , linearly correlated with the increased HRs from 400 to 650 beats/min; Fig. 4E ). The slope of the relationship between HR and/or RPP and CF in A 2A/2B DKO mice was not significantly different from that in WT mice, suggesting that neither A 2A ARs nor A 2B ARs are required for the pacing-induced increase in CF.
Effect of catalase on pacing-induced coronary hyperemia. The role of H 2 O 2 in pacing-induced hyperemia was examined in WT mice (n ϭ 6) before and after the addition of catalase (2,500 U/ml). Catalase significantly decreased CF from 16.5 Ϯ 1.22 to 13.8 Ϯ 1.40 ml·min Ϫ1 ·g Ϫ1 (Fig. 5A ) and significantly decreased LVDP from 96 Ϯ 7.4 to 88 Ϯ 7.1 mmHg (Fig. 5C ), respectively (P Ͻ 0.05 by paired t-test). Additionally, catalase significantly attenuated the pacing-induced increase in CF by ϳ37% (the net increase in CF of hearts paced from 400 to 650 beats/min was decreased from 7.4 Ϯ 0.12 to 4.6 Ϯ 0.49 ml·min Ϫ1 ·g
, P Ͻ 0.05). The slope of the relationship between HR and/or RPP and CF in the presence of catalase was significantly lower than that under control conditions (P Ͻ 0.05 by paired t-test; Fig. 5, A and B) .
Effect of glibenclamide on pacing-induced coronary hyperemia. The role of K ATP channels in pacing-induced coronary hyperemia was determined in isolated WT mouse hearts (n ϭ 6) in the absence or presence of glibenclamide (K ATP channel blocker, 5 M). In the absence of glibenclamide, CF increased by 6.2 ml·min Ϫ1 ·g Ϫ1 after hearts were paced from 400 to 650 beats/min (Fig. 6, A and B) . After glibenclamide infusion, CF decreased significantly by ϳ 45% (from 20 Ϯ 1.6 to 11 Ϯ 0.9 ml·min Ϫ1 ·g Ϫ1 , P Ͻ 0.05; Fig. 6 , A and B) and LVDP was reduced by ϳ36% (from 112 Ϯ 13.3 to 72 Ϯ 7.0 mmHg, P Ͻ 0.05; Fig. 6C ). Moreover, pacing-induced hyperemia was dramatically decreased by ϳ94% (the net CF increase before and after glibenclamide was 6.1 and 0.39 ml·min Ϫ1 ·g
, respectively; Fig. 6, A and B) . The dramatic reduction in functional hyperemia was concomitant with a significant decrease in LVDP during pacing (LVDP decreased from 72 Ϯ 7.0 to 63 Ϯ 9.0, 57 Ϯ 4.8, and 59 Ϯ 9.2 mmHg when hearts were paced at 550, 600, and 650 beats/min, respectively; Fig. 6C ), suggesting compromised heart function as a result of an imbalance between O 2 supply and demand after K ATP channel blockade.
DISCUSSION
In the present study, using targeted AR KO mice combined with pharmacological approaches, we further examined the role of adenosine, H 2 O 2 , and K ATP channels in coronary metabolic hyperemia. In isolated Langendorff-perfused mouse hearts from A 2A KO, A 2B KO, and A 2A/2B DKO mice, we demonstrated that adenosine and its receptor subtypes (A 2A and A 2B ) are not required for pacing-induced coronary metabolic hyperemia, although they exert important roles in maintaining CF under resting conditions. Similarly, broad pharmacological blockade of ARs by 8-SPT in the absence or presence of a NO synthase inhibitor or selective A 2A AR and A 2B AR blockade did not affect pacing-induced increase in CF, although baseline flow was reduced. However, K ATP channel blockade by glibenclamide remarkably reduced both resting flow and pacing-induced hyperemia, resulting in a dramatic decrease in LVDP. Scavenging of H 2 O 2 by catalase also decreased resting flow and pacing-induced coronary hyperemia but to a lesser extent than glibenclamide. Our results suggest that while adenosine modulates coronary vascular tone under both resting and ischemic conditions, it is not required for metabolic hyperemia even when the NO pathway is inhibited. However, H 2 O 2 and K ATP channels are important local control mechanisms responsible for both coronary ischemic and metabolic vasodilation.
Since Berne (6) proposed that adenosine is an important metabolite that links the changes in CF to mvO 2 , there have been numerous studies that have examined the adenosine hypothesis in coronary metabolic hyperemia (3, 4, 7, 14, 21, (47) (48) (49) . Early studies supported this hypothesis in that the augmentation in cardiac interstitial adenosine concentration was observed to be correlated with increased mvO 2 in chronically instrumented dogs (3, 19, 21 ) and pharmacological block-ade of ARs was shown to decrease coronary metabolic hyperemia in isolated guinea pig hearts (21) . However, more recent studies in awake dogs have reported that there was no significant increase in cardiac interstitial adenosine levels that was sufficient to cause coronary vasodilation (49, 50, 52) and that AR blockade (49, 50) or triple blockade of adenosine, K ATP channels, and NO (47, 48) did not affect exercise or norepinephrine-induced coronary hyperemia, suggesting that adenosine is not required in coronary functional hyperemia. Interestingly, Duncker and colleagues (16, 17) suggested that adenosine is an important mediator for coronary metabolic hyperemia only when the K ATP channel is blocked or under conditions where coronary perfusion pressure is reduced. The discrepancies among these studies may be due to the mixed drug specificity or to the complexity of mixed local and neuronal control mechanisms responsible for coronary blood flow regulation under in vivo conditions. Using targeted AR KO mice combined with an isolated heart preparation to solve the specificity , n ϭ 6 ). E and F: the relationship between HR and CF (E) and the relationship between RPP and CF (F) were compared between WT mice (n ϭ 6) and A2A/2BAR double-knockout (A2A/2B DKO) mice (n ϭ 6). *P Ͻ 0.05, significant difference between the curves or significant different versus control.
issue as well as to exclude the neurohormonal effect on CF regulation, the present study showed that A 2A ARs and A 2B ARs are important in modulating coronary vascular tone under resting conditions because baseline CF in A 2A KO, A 2B KO, and A 2A/2B DKO mice was reduced (by ϳ16%, ϳ18%, and ϳ24%, respectively) compared with WT mice (Figs. 3 and 4 or CVT-6883 (1 M) also resulted in a significant reduction (by ϳ25%, ϳ35%, and ϳ18%, respectively) in resting CF (Figs. 1, 3 , and 4). In agreement with our findings, other studies in humans (18) , pigs (14) , dogs (49) , and isolated guinea pig hearts (21) have also reported that adenosine is involved in modulating CF under resting condition. Of note, a lower reduction in CF was observed in A 2A KO mice (by ϳ18%) versus SCH-58261-treated animals (by ϳ35%; Fig. 3, A and  C) . The lower reduction in baseline CF might be due to upregulated A 2B ARs in A 2A KO mice compared with WT mice, as previously reported (45 , and HR and LVDP (C) before and after the addition of catalase (the enzyme that decomposes H2O2 to water, 2,500 U/ml, n ϭ 6). *P Ͻ 0.05, significant difference in the slope of the linear curves (A and B) and significant difference versus control (C, paired t-test). mechanisms of adenosine in modulating resting CF, our results (45) and those of others (56) suggest that A 2A AR-mediated NO production may be responsible for resting tone regulation because 8-SPT (nonselective adenosine antagonist; Fig. 2 ) or SCH-58261 (selective A 2A AR antagonist) (56) failed to further decrease baseline CF in the presence of a NO synthase inhibitor. Concomitant with the decreased baseline flow, a significant reduction in LVDP (Table 1 and Figs. 1C, 3C, and 4D ) and a relatively but not statistically lower ϩdP/dt (Table 1) were observed upon blockade of adenosine either pharmacologically or genetically. The correlated decrease in cardiac contraction with the decreased CF suggest that adenosine is an important mediator involved in modulating resting CF and that the decreased cardiac function is associated with the decreased CF.
Despite the decrease in resting CF, pacing-induced hyperemia was not affected after AR blockade or deletion, in as much as the linear curve of the relationship between HR and/or RPP and CF was downward shifted in a parallel manner and the slope of the curve was not altered before or after AR blockade or deletion (Figs. 1, 3, and 4) . These results, obtained from targeted AR KO mice, add further evidence to the previous findings that an AR blocker failed to inhibit exerciseinduced coronary hyperemia in chronically instrumented dogs, although it lowered the balance between O 2 supply and delivery under resting conditions (47, 49) . The approach of using targeted AR KO mice allowed us to rule out the possibility that increased endogenous adenosine overcomes the competitive receptor blockade, thus masking the direct AR blockade effect. Additionally, in the presence of a NO synthase inhibitor, 8-SPT did not further decrease resting flow as well as pacing-induced coronary hyperemia, indicating both NO and adenosine act as tonic vasodilator but are not required for coronary metabolic hyperemia.
Increasing evidence suggests that H 2 O 2 , an endogenous metabolite, acts as a pivotal mediator responsible for metabolic coronary vasodilation (37, 42, 53, 54) . In support of this idea, our results showed that catalase significantly decreased resting CF (by ϳ16%) as well as the pacing-induced increase in CF (by ϳ37%; Fig. 5, A and B) . It should be pointed out that although A 2A AR-mediated H 2 O 2 production in the coronary endothelium and smooth muscle cells has been previously reported to play an important role in coronary ischemic hyperemia (42, 57) , the failure of AR blockade or deletion to reduce metabolic hyperemia (discussed above) suggest that other mechanisms than adenosine-mediated signaling are responsible for H 2 O 2 production, thus contributing to coronary metabolic vasodilation. Regarding the source of H 2 O 2 , we speculate that mitochondrial electron transport in cardiomyocytes might be an important source for pacing-induce H 2 O 2 production (37).
The K ATP channel has been reported to be involved in coronary ischemic vasodilation (24, 41, 42, 57) , although its role in metabolic vasodilation remains controversial (13, 15, 23, 35, 47, 55) . In isolated mouse hearts, the present study showed that glibenclamide (5 M) significantly reduced CF (by ϳ45%; Fig. 6A ) and LVDP (by ϳ36%; Fig. 6C ) at rest. In agreement with our results, studies in dogs have reported that intracoronary infusion of glibenclamide (50 -80 g·kg Ϫ1 ·min Ϫ1 ) significantly decreased baseline flow (by ϳ20 -50%) (38) and was associated with cardiac contractile dysfunction (systolic wall thickening decreased by ϳ43%) (15) . Importantly, recovery of the CF rate to preglibenclamide levels after the addition of sodium nitroprusside reversed the cardiac dysfunction, suggesting that K ATP channels exert essential roles in maintaining resting CF and that the decreased CF upon K ATP channel blockade in the coronary vasculature causes ischemia-induced cardiac contractile dysfunction (15) . It is important to note, however, that K ATP channels at concentrations of Ͼ10 M have been reported to inhibit other K ϩ and Ca 2ϩ channels (5, 36) . The concentration we used in the present study (5 M) is within its selectivity range (5, 36) , thus strengthening our conclusion that the K ATP channel is important in modulating resting CF. Interestingly, in disagreement with the majority of studies showing that blockade of K ATP channels did not attenuate the increase in CF during treadmill exercise or paired cardiac pacing in dogs and pigs (13, 15, 34, 35, 47) , the present study on isolated mouse hearts demonstrated that blockade of K ATP channels not only reduced resting flow but also markedly inhibited pacing-induced functional hyperemia by ϳ94% (Fig. 6, A and B) . The discrepancy among the studies could be due to 1) species differences (mice vs. pigs and dogs) or 2) the difference in animal models (isolated hearts vs. whole animals). In isolated hearts from mice deficient in K ir 6.1 (one of the K ATP subunits), isoprenaline-induced coronary vasodilation was significantly attenuated, indicating an important role of K ATP channels in coronary metabolic hyperemia (55) . Additionally, the redundant mechanisms responsible for CF regulation in whole animals, including local and neurohormonal control mechanisms, may complicate the explanation of the data, e.g., the reduction of coronary metabolic hyperemia by the K ATP channel blocker might be compensated by an enhanced neurohormonal effect or other unknown mechanisms to maintain the balance between O 2 supply and demand, thus resulting in unchanged metabolic hyperemia in vivo even after K ATP channel blockade. Concomitant with the reduced metabolic hyperemia in isolated mouse hearts, we also observed dramatic cardiac contractile dysfunction. In contrast to significant increases in LVDP upon pacing in control condition, K ATP channel blockade resulted in a significant reduction in LVDP upon pacing (Fig. 6C) , suggesting potential ischemic cell damage related to a decrease in CF.
It is well established the K ATP channels play important roles in adenosine-mediated coronary reactive hyperemia (1, 8, 22, 41, 42, 57) . Our recent studies (42, 58) have demonstrated that A 2A AR-mediated H 2 O 2 production opens K ATP channels, partially contributing to coronary reactive hyperemia. In these studies, although adenosine-induced K ATP current was reduced in A 2A KO and A 2A/2B DKO animals, pinacidil (K ATP opener)-induced current was not affected after deletion of both A 2A ARs and A 2B ARs, suggesting that A 2A ARs and A 2B ARs are not required for K ATP activation and that the absence of ARs does not affect channel expression, as we previously reported (33, 42) . Additionally, we demonstrated that K ATP channel blockade inhibited coronary reactive hyperemia (57) to a higher extent than A 2A AR blockade, indicating that other factors, including adenosine, can also activate K ATP channels, thus contributing to coronary vasodilation. In the present study, K ATP channel blockade dramatically decreased metabolic hyperemia, whereas only a parallel downward shift of the relationship between CF and RPP was observed upon A 2A AR and/or A 2B AR blockade or ablation, suggesting that other unknown mediators than adenosine released during increased cardiac metabolic demand can activate K ATP channels, contrib-uting to the increased flow during metabolic hyperemia. One of the mediators appears to be H 2 O 2 , because scavenging of H 2 O 2 by catalase significantly decreased metabolic hyperemia by ϳ37% (Fig. 5, A and B) and to a lesser extent than K ATP channel blockade (by ϳ94%; Fig. 6, A and B) . Taken together, our results suggest that while adenosine-mediated H 2 O 2 production and K ATP channel opening are important for coronary reactive hyperemia, adenosine appears to be not required for metabolic hyperemia, and other unknown mediators act together with H 2 O 2 to open K ATP channels and are thus responsible for metabolic hyperemia in isolated mouse hearts.
It should be pointed out that there are some limitations regarding the translation of our findings based on our present experimental model into the clinical applications regarding the pathophysiology of CF regulation. First, although the effects of neurohomonal and blood components were excluded to scrutinize the metabolic control mechanism in CF regulation, buffer-perfused isolated hearts did not allow us to clearly separate the contribution of shear-and/or pressure-induced CF changes from local metabolic effects. Second, the continuously oxygenated (95% O 2 ) Krebs buffer used in isolated hearts has much less O 2 carrying capacity than blood, which might cause hypoxia and relatively lower cardiac contractile function compared with blood-perfused hearts (40) . However, in bufferperfused hearts paced from 400 to 600 beats/min, we observed a correlated increase in mvO 2 from 160 to 230 l·min Ϫ1 ·g Ϫ1 as well as CF (increased by ϳ40%). More importantly, CF increased more than twofold over baseline after 15-s flow occlusion (42, 57) , indicating that buffer-perfused hearts have a minimum hypoxia and coronary vessels have the capacity to further dilate. However, due to the relatively lower myoglobin O 2 saturation in buffer-perfused hearts (39), the cardiac interstitial adenosine level might be higher compared with bloodperfused hearts, which may overestimate the role of adenosine in modulating resting coronary blood flow in our model. Future studies are needed to compare adenosine levels in bufferversus blood-perfused hearts. Finally, to extend our study to an atherosclerotic model, where blunted metabolic hyperemia has been reported, it should be noted that other factors, such as phenotypic changes of coronary vessels (more stiff and fibrotic) and hemodynamic alterations due to collateral circulation and/or coronary steal (less flow to the ischemic region where the vascular network is already maximally dilated), need to be considered for studies.
In conclusion, blockade of ARs, in particular, A 2A ARs and A 2B ARs using combined pharmacological compounds with targeted gene deletion, decreased CF at rest but failed to reduce the pacing-induced increase in CF. Inhibition of NO synthase decreased resting CF without an effect on pacing-induced hyperemia, which was not altered by combined blockade of ARs, suggesting both NO and adenosine are not required for coronary metabolic hyperemia. The mechanisms responsible for pacing-induced coronary hyperemia involve mostly K ATP channels and, to a lesser extent, H 2 O 2 , since blockade of K ATP channels by glibenclamide almost abolished pacing-induced coronary vasodilation, whereas scavenging of H 2 O 2 by catalase only partially inhibited the response. Thus, although adenosine-mediated H 2 O 2 production and the subsequent opening of K ATP channels in the coronary vasculature play an important role in coronary ischemic vasodilation, other mechanisms, but not adenosine, are responsible for H 2 O 2 production and opening of K ATP channels, leading to coronary metabolic vasodilation in isolated mouse hearts.
A compromised coronary vasodilation may not necessarily cause ischemia under resting condition. However, during increased myocardial demand, e.g., exercise, the coronary vascular dysfunction will lead to a mismatch between O 2 demand and supply, manifesting the clinical symptom known as angina. Although mice differ significantly from humans in many aspects, which may limit the extrapolation of present study to clinical situations, our model, using paced mouse hearts to gradually increase rates that are within the range of HR change during exercise in humans, will provide an important basis for further mechanistic studies in humans. The different mechanisms regarding the roles of adenosine, H 2 O 2 , and K ATP channels in CF regulation during ischemic versus metabolic hyperemia may add new knowledge to the understanding of pathophysiology of coronary artery diseases.
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